A comprehensive profile of THC: from ancient medicine to modern controversy
A thorough review of THC covers its chemistry, pharmacology as a CB1 partial agonist, approved therapeutic uses for pain and nausea, and the ongoing debates around psychosis risk, cognitive impairment, and addiction potential.
Quick Facts
What This Study Found
THC primarily acts as a partial agonist at CB1 receptors, producing its distinctive intoxication. It is approved for chronic pain, chemotherapy-induced nausea/vomiting, and MS spasticity, and is being investigated for anorexia nervosa, dementia agitation, and Tourette syndrome. Robust debates continue around its capacity to produce psychosis, cognitive impairment, and its addictive and gateway potential.
Key Numbers
192 million estimated cannabis users globally. THC available as Marinol, Sativex, and Namisol. Approved indications: chronic pain, chemotherapy nausea/vomiting, MS spasticity. Under investigation: anorexia nervosa, dementia agitation, Tourette syndrome.
How They Did This
Comprehensive narrative review covering THC chemistry, pharmacology, therapeutic uses, history, and societal context as part of the "Dark Classics in Chemical Neuroscience" series.
Why This Research Matters
With an estimated 192 million cannabis users globally, understanding THC at the molecular, clinical, and societal level is essential. This review serves as a definitive reference point for the science and controversies surrounding the world's most widely used illicit psychoactive compound.
The Bigger Picture
THC occupies a unique position as simultaneously an ancient medicine, a modern pharmaceutical, and the world's most popular illicit drug. The scientific and social controversies surrounding it reflect deeper tensions about drug policy, individual liberty, and the boundaries of therapeutic evidence.
What This Study Doesn't Tell Us
As a narrative review, this does not provide systematic evidence synthesis or meta-analysis. The breadth of topics covered means individual areas receive less depth than dedicated reviews.
Questions This Raises
- ?Will the expanding legal landscape lead to better understanding of THC risks and benefits?
- ?Can the psychosis and cognitive impairment risks be separated from therapeutic benefits through dose optimization or novel formulations?
- ?How does partial agonism at CB1 explain THC's unique pharmacological profile?
Trust & Context
- Key Stat:
- 192 million users globally
- Evidence Grade:
- Rated strong because this is a comprehensive, authoritative review published in a major neuroscience journal synthesizing decades of research.
- Study Age:
- Published in 2019. Cannabis research, policy, and legalization have continued to evolve rapidly since.
- Original Title:
- Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.
- Published In:
- ACS chemical neuroscience, 10(5), 2160-2175 (2019)
- Authors:
- Banister, Samuel D(4), Arnold, Jonathon C(28), Connor, Mark(2), Glass, Michelle, McGregor, Iain S
- Database ID:
- RTHC-01932
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What does THC do in the brain?
THC acts primarily as a partial agonist at CB1 cannabinoid receptors, which are found throughout the brain. This produces its characteristic intoxication, pain relief, appetite stimulation, and other effects.
What is THC approved to treat?
THC is approved for chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. It is being investigated for other conditions including anorexia nervosa and Tourette syndrome.
Is THC addictive?
THC has recognized addictive potential, though the severity and prevalence of cannabis use disorder are debated. The review notes this as one of the major ongoing scientific controversies.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01932APA
Banister, Samuel D; Arnold, Jonathon C; Connor, Mark; Glass, Michelle; McGregor, Iain S. (2019). Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.. ACS chemical neuroscience, 10(5), 2160-2175. https://doi.org/10.1021/acschemneuro.8b00651
MLA
Banister, Samuel D, et al. "Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabinol.." ACS chemical neuroscience, 2019. https://doi.org/10.1021/acschemneuro.8b00651
RethinkTHC
RethinkTHC Research Database. "Dark Classics in Chemical Neuroscience: Δ9-Tetrahydrocannabi..." RTHC-01932. Retrieved from https://rethinkthc.com/research/banister-2019-dark-classics-in-chemical
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.